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SUMMARY
We have deliberately targeted collaboration between T cells and certain B cells by using a
heteroconjugate (HETCONJ) antibody. This specific reagent was created by cross-linking the F(ab')2
portions of anti-I-Ab and anti-CD3 monoclonal antibodies. Spleen cells from B6 (I-Ab) but not bml2
(I-Abml2) mice proliferated in vitro in the presence ofthe HETCONJ. Similarly, T-cell dependent IgM
secretion was induced in B cells from B6, yet only weakly in B cells from bm 12 mice. Using B cells
from Igh allotype double congenic (B6.C20 Igha/I-Ab and bml2, Ighb/I-AbmI2) mice in co-culture
experiments, we have used the HETCONJ to study linked versus bystander T-B interaction. B-cell
activation, mediated by HETCONJ, was 10 times greater in unseparated than in resting splenic
B cells. T-B interaction through T-B contact was more efficient than activation through bystander
effects both for unseparated and resting splenic B cells. Large, already activated B cells, in contrast,
did not show a preference for linked recognition. Our reagent has mimicked some of the events
involved in T-B collaboration and may be useful in studying the molecular basis of cellular
interactions.
INTRODUCTION
B-cell responses against thymus-dependent antigens (Ag)
require specific T-helper cell activation and release of factors.",2
This complex interaction involves processing of the Ag which is
then presented to T cells in conjunction with Ia molecules.3 In
vitro and in vivo studies have compared the requirements for
cognate (through specific recognition)4-6 and bystander (non-
specific, through lymphokines)7 B-cell activation. In specific
T-B interaction, a trimolecular complex composed of T-cell
receptor (TcR)-Ag-Ia is formed8 and contributes to T-B
conjugation. In addition, adhesion molecules appear to stabilize
this conjugate.9"10 In non-specific T-B interaction, B cells are
thought to be activated by T-cell factors without the involve-
ment of a specific TcR-Ag-Ia complex. In that case, however,
the role of adhesion molecules is not excluded. To study and
control these interactions, artificial ways of mimicking them
have been devised. The original one described linked recogni-
tion through the carrier-hapten effect." More recently, cross-
linking of anti-myoglobin or anti-ferritin antibodies to anti-
mouse Ig,'2"13 or anti-major histocompatibility complex (MHC),
or anti-Ig to anti-DNP'4 have been shown to enhance B-cell
presentation of specific antigens and induce in vivo responses to
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weak antigens. Anti-Thy-l-TNP conjugates were also used to
show the importance of T-cell activation via the TcR in T-B co-
operation.'5
In this paper, we have mimicked some of the events involved
in T-B co-operation by broadly targeting two of the molecules
specifically involved in this interaction: CD3 on T cells and I-A
on B cells. Anti-CD3 antibodies have been shown to induce T-
cell activation.'6 Ia molecules have been implicated in trans-
membrane signalling to B cells. 17 The F(ab')2 fragments of these
monoclonal antibodies (mAb) were coupled to each other to
give a bispecific, heteroconjugate (HETCONJ) reagent. We
used mice doubly congenic for I-A (I-Ab and I-Abm12) and IgM
allotype (Igha and Ighb) to compare linked and bystander T-B
interaction in co-culture experiments.
MATERIALS AND METHODS
Mice
(Table 1) I-A co-isogenic C57BL/6Kh (B6, I-Ab, Ighb) and B6.C-
H-2 bml2 (bml2, I-AbmI2, Ighb) mice were originally obtained
from Dr R. Melvold (Northwestern University, Chicago, IL)
and maintained in our colony. C57BL/6.C-20 (B6.C20, I-A",
Igha) mice were obtained from Dr G. Bosma (Institute for
Cancer Research, Philadelphia, PA). (B6.C20 x bml 2)FI mice
were produced in our colony. Three- to six-month-old mice of
both sexes were used.
Antibodies
Rat 1gM anti-Thy-1.2 (AT83),'8 anti-CD8,19 and anti-CD420
mAb were used for complement-mediated cytotoxicity. Hams-
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Table 1. MHC haplotypes and Ig allotypes
of mice used
Mouse strain Class II Igh
B6.C20 I-Ab a
bml2 I-Abml2 b
(B6.C20 x bml2) F1 I-Ab/I-Abml2 a or b
ter IgG anti-murine CD3 mAb (145-2Cl = 2CI 1, a gift from
Dr J. Bluestone, University of Chicago, Chicago, IL)2' was
purified as described elsewhere22 from serum-free supernatant
(grown in HB 102 medium; Hana Biologics, Alameda, CA) over
HPLC (Millipore, Waters, Milford, MA) ion-exchange col-
umns. Murine IgG2a anti-I-Ab mAb (D3-137.5), a gift from Dr
S. Tonkonogy (North Carolina State University, Raleigh, NC),
was purified from ascites by precipitation with ammonium
sulphate, followed by protein A column (Sigma, St Louis, MO)
separation. Anti-allotype mAb HB100 (antiIgMa, rat IgGl)23
and AF6-78.25 (anti-IgMb, mouse IgGl)24 were obtained,
respectively, from American Type Culture Collection, Rock-
ville, MD and from Dr A. M. Stall (Stanford Medical School,
Stanford, CA).
F(ab')2 heteroaggregate preparation
F(ab')2 fragments were prepared by 1% pepsin digestion at 37°
of mAb in 0-5 M sodium acetate (pH 4-5) for 16 hr. They were
then separated over a Sephadex G 200 (Pharmacia, Piscataway,
NJ) column followed by further purification with a protein A
column (for 145-2C1 1) or an anti-mouse pFc' column (for D3-
137.5). The conjugation of F(ab')2 fragments of the two mAb
was performed as described elsewhere.25. Briefly, F(ab')2 frag-
ments in phosphate buffer (pH 7 5) were incubated separately
for 2 hr at room temperature in the presence ofan 8 molar excess
of N-succinimidyl 3-[2-pyridyldithio]-propionate (SPDP);
Sigma). 145-2CI 1 F(ab')2 were then treated with dithiothreitol
(0-02 M; Sigma) and added to D3-137.5 F(ab')2. After 9 hr of
incubation at room temperature, 300 mg of iodoacetamide
(Sigma) were added. The heteroconjugates were separated over
a Sephadex G 200 column, sterilized by filtration, and kept at 4°.
Preparation of cells
Mice were killed by cervical dislocation and spleens were
removed aseptically. Single-cell suspensions were prepared in
Dulbecco's modified Eagle medium (DMEM; Hazelton
Research Products, Denver, PA) supplemented with 10 mM
HEPES. B cells from B6.C20 and bml2 mice were prepared
from spleen cells by complement-mediated cytotoxicity using a
mixture of anti-Thy-1.2, anti-CD8 and anti-CD4 mAb. Spleen
cells from (B6.C20xbml2) F1 mice were enriched for CD4+
cells with a panning technique using Petri dishes coated with a
previously determined optimal concentration of goat anti-
mouse IgM antiserum followed by treatment with anti-
CD8+complement. Small and large B cells were prepared by
separation of purified B cells over a Percoll gradient, as
described elsewhere.26 Small B cells were taken at the 60-70%
interface and large B cells at the 50-60% interface.
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Figure 1. Schematic description of the allotype-specific plaque assay.
Cell cultures
All cultures were performed in DMEM supplemented with non-
essential amino acids, 10 mm HEPES, 5 x 10-5 M 2-mercap-
toethanol, 100 jg/ml streptomycin, 100 U/ml penicillin and
10% foetal calf serum (FCS; Hazelton). Proliferation assays
were performed in 96-well round-bottomed microtitre plates
(Corning, Houston, TX). Cells (105 cells/well) in 200 pl were
cultured in the presence ofvarious doses ofmAb or heteroconju-
gate at 370 in an incubator containing 5% CO2 in humidified air.
One pCi of [3H]thymidine ([3H]TdR; ICN, Irvine, CA) was
added to each well after 40 hr of culture and incubated for 8 hr
before harvest with an automated device (PhD harvester,
Cambridge Technology, Cambridge, MA). One-millilitre cul-
tures were performed in 24-well plates (Costar, Cambridge,
MA). B6.C20 and bml2 B cells were co-cultured at 0-8 x 106
cells/ml in the presence or absence of 5 x 104 (B6.C20 x bml2)FI
CD4+-enriched T cells for 4 days. Unconjugated mAb and
heteroconjugates were added at the indicated concentrations.
As controls, B cells from B6.C20 or bmI2 mice were cultured
separately with heteroconjugate or with lipopolysaccharide
(LPS) 055:B5 (Difco, Detroit, MI) (50 pg/ml).
Allotype-specific IgM plaque-forming cell (PFC) assay
(Figure 1) Antibodies were coupled to sheep red blood cells
(SRBC). Equal volumes of packed SRBC, chromic chloride
(Mallinkrodt, St Louis, MO) (0 5 mg/ml), and antibody (50 Mg/
ml of HB1OO or 100 pg/ml of AF6-78.25) were incubated at
room temperature for 25 min in normal saline. After three
washes in saline, the antibody-coupled SRBC were diluted 1/10
in Hanks' balanced salt solution (Tissue Culture Facility,
Lineberger Cancer Center, Chapel Hill, NC) containing 100 Mg/
ml streptomycin, 100 U/ml penicillin, 10 mm HEPES, and
0-075% NaHCO3 (HBSS). The coupling efficiency was evalu-
ated in an agglutination assay using anti-mouse IgG I and anti-
rat IgGI antisera. The PFC assay was performed as described
elsewhere.27 Briefly, cells were harvested from culture wells,
washed three times, and suspended in 1 ml of HBSS. Cells (100
Ml/well) were distributed in triplicate in flat-bottomed microtitre
plates (Corning, Houston, TX). Ten microliters of a 10%
solution ofSRBC coupled either with HB100 or with AF6-78.25
were then added, and the plates were centrifuged and allowed to
incubate for 1 hr at 370 in 5% CO2 in air. Goat anti-mouse IgM
antiserum (10 pl/well, final dilution 1/100) and guinea-pig
complement (Pel-Freez, Rogers, AR) (10 pl/well, final dilution
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Figure 2. Induction of B6 spleen cell proliferation by the HETCONJ.
Spleen cells (105/well) from B6 (filled symbols) or bml2 mice (empty
symbols) were cultured in triplicate in the presence of 1 ug/ml of anti-
CD3 (2CI 1), 30 jg/ml of F(ab')2 fragments of 2C1 and anti-I-Ab
(D3-137.5), or varying doses of the anti-CD3/anti-I-Ab HETCONJ.
[-] B6+HETCONJ; (0) bml2+HETCONJ; (A) B6+2Cll; (A)
bml2 + 2C1 1; (0) B6+ F(ab')2 anti-CD3 + F(ab')2 anti-1-Ab; (0)
bm 12 + F(ab')2 anti-CD3 + F(ab')2 anti-I-Ab.
1/13) were added together to each well and the plates further
incubated at 370 for 90 min. PFC were counted using a dark field
stereo microscope.
RESULTS
2C11/D3-137.5 heteroconjugate (HETCONJ)-specific prolifer-
ation of B6 spleen cells
The bispecific HETCONJ was first tested for its capacity to elicit
spleen cell proliferation. B6 and bml2 spleen cells were
incubated separately in the presence of various dilutions of
HETCONJ. IgG (whole molecule) anti-CD3 antibody was used
as a positive control. As shown in Fig. 2, both B6 and bml2
spleen cells responded well to anti-CD3. However, the HET-
CONJ induced efficient proliferation of only B6 spleen cells,
demonstrating the specificity of this reagent. A mixture of
F(ab')2 fragments of anti-CD3 and anti-I-Ab (30 yg/ml) had no
effect either on B6 or on bm 12 spleen cells.
Specificity of PFC assay for IgMa and IgMb
LPS-stimulated B cells were tested to demonstrate the specificity
of the allotype PFC assay. As shown in Fig. 3a, only IgMa
allotype PFC were detected when B6.C20 B cells were cultured
with LPS. Conversely, only IgMb allotype PFC were detected
with bml2 B cells cultured with LPS. Moreover, similar
numbers of PFC were obtained with B6.C20 and bml2 B cells,
implying comparable sensitivity in the detection of either
allotype. When B6C.20 and bml2 B cells were co-cultured,
similar numbers of PFC of both allotypes were detected. These
results established that PFC of both allotypes could be discrimi-
nated and that co-culture of IgMa with IgMb B cells did not
influence the number of PFC specific for each allotype. As
expected, LPS-stimulated F1 B cells produced similar amounts
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Figure 3. Linked and bystander T-B interaction in splenic B cells. (a)
Allotype plaque assay specificity. 0 5 x 106 B cells from B6.C20, bm l 2 or
(B6.C20 x bml2)Fl mice were co-cultured or cultured separately for
4 days in the presence of 50 pg/ml of LPS. The allotype-specific plaque
assay was then performed in triplicate. (b) HETCONJ specificity. B cells
from B6.C20 and bml2 mice (106/well) were cultured separately in the
presence of 5 x 104 F CD4 +-enriched T cells and the HETCONJ (3 mg/
ml). (c) Linked versus bystander effect. Mixtures of B6.C20 and bm 12 B
cells were co-cultured as described in (b) in medium alone, in the
presence of a mixture of F(ab')2 antibodies (1 5 ,ug/ml), or the
HETCONJ (3 yg/ml). As a control (B6.C20 x bml2)Fl B cells were
cultured in the same conditions. After 4 days, an allotype-specific plaque
assay was performed. The results are expressed as PFC/ 106 B cells. One
standard deviation did not exceed 10% when responses were above
background.
Targeting of B-cell activation with 2C1l/D3-137.5 HETCONJ
Figure 3b shows typical results obtained when B6.C20 and
bm12 B cells were cultured separately in the presence of
HETCONJ. In the presence of (B6.C20 x bml2)F, CD4+-
enriched T cells, B6.C20 B cells exhibited a substantial acti-
vation as determined by the large numbers of IgMa PFC. As
would be predicted, no IgMb PFC were seen. On the other hand,
bml2 B cells, bearing Ta molecules which are non-reactive with
the HETCONJ, showed little IgMb secretion and no JgMa
secretion.
Linked versus bystander effect in HETCONJ stimulation
To determine the importance of linked versus bystander effects
in HETCONJ-mediated T-B interaction, we co-cultured
B6.C20 and bml2 B cells in the presence of (B6.C20 x bml2)F,
CD4+ cells either in medium alone, with a mixture of F(ab')2
antibodies, or with HETCONJ. As a control,
3
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Figure 4. Linked and bystander T-B interaction in small B cells. See
Fig. 3 legend. T-depleted spleen cells were separated over a Percoll
gradient into small and large B cells. Co-culture experiments as
described in Fig. 3 were performed using 106 B cells and 2 x 104 CD4+-
enriched F, T cells. HETCONJ was used at 0-3 ,g/ml and the F(ab')2
fragments at 0-15 jug/ml. An allotype plaque assay was performed after
4 days of culture.
(B6.C20 x bml2)F, B cells were cultured in the same conditions.
As shown in Fig. 3c, few plaques were detected after culture with
a mixture of F(ab')2 fragments of the anti-CD3 and anti-I-Ab
mAb. Furthermore, in the absence of T cells, little B-cell IgM
secretion was seen. In the presence of F, T cells and HETCONJ,
however, more IgMa than IgMb PFC (9600 versus 6100) were
observed, indicating a preference for cognate interaction,
although substantial bystander effect was observed. F, B cells, in
contrast, produced an equal number of IgMa and IgMb PFC.
Similar results were obtained in a total of four experiments, and
the mean (± 1 SD) ratio of HETCONJ/T cell-induced B6.C20
(linked) PFC to bml2 (bystander) PFC was 1-94 (±0-31).
Linked versus bystander effect on small and large B cells with
HETCONJ stimulation
Unseparated splenic B cells represent a mixture of activated and
resting B cells. To determine the relative dependence on linked
T-B interaction of the two populations, we separated them over
a Percoll gradient and cultured them under various conditions.
Control stimulation with LPS (Fig. 4a) showed some excess of
IgMa over IgMb in B6.C20+bml2 co-cultures. However, when
B6.C20 or bml2 B cells were cultured separately in the presence
of LPS, they produced equivalent amounts of their respective
IgM, while F, B cells also generated similar amounts of IgMa
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Figure 5. Linked and bystander T-B interaction in large B cells. See
Fig. 4 legend.
activation of B6.C20 small B cells but not of bml2 small B cells
(Fig. 4b). In mixtures of bml2 and B6.C20 B cells, no
stimulation was observed either in the absence ofHETCONJ or
T cells, or in the presence of unconjugated F(ab')2 fragments
(Fig. 4c). In the presence ofHETCONJ and T cells, the number
ofPFC in small B cells was greatly reduced compared with what
was usually seen in total B cells (940 in Fig. 4c versus 9600 in Fig.
3c). IgMa PFC were more abundant than IgMb (940 versus 240,
linked/bystander ratio = 3 6) (Fig. 4c). Another experiment gave
a 2-6 ratio (linked/bystander mean ratio = 31- + 0-71).
Large B6.C20 + bml2 B cells stimulated with LPS showed a
somewhat higher representation of IgMa (Fig. 5a). In the
presence of HETCONJ, large B6.C20 B cells showed a high
IgMa response whereas bml2 B cells showed, as predicted, no
response (Fig. 5b). Spontaneous IgM production (Fig. 5c) [i.e.
in the absence of HETCONJ or in the presence of F(ab')2] was
higher (2400 PFC/106 B cells) than in unseparated B cells (500
PFC/106 B cells, see Fig. 3) or in small B cells ( < 100 PFC/106 B
cells, Fig. 4b), indicating in vivo B-cell activation. The B-cell
response in the presence of HETCONJ was also higher in large
B cells than in unseparated B cells (Fig. 5c, 22880 PFC/106 B
cells, versus Fig. 3, 9600 PFC/106 B cells). The bystander
response was greater than in the unseparated B-cell population.
(Fig. Sc, 22880 PFC/106 B6.C20 B cells, versus 16120 PFC/106
bml2 B cells). Linked/bystander ratio was 1-4. Another experi-
ment gave a 1 1 ratio (mean ratio= 1-25+0-21).
DISCUSSION
We have developed a specific heterobifunctional reagent which






Heteroconjugate antibody-induced T-B interaction
may mimic normal T-B collaboration. The reagent consists of
the F(ab')2 fragments of two mAb which are covalently bound
to each other. One reagent recognizes the epsilon subunit of the
CD3 component of the TcR complex. The other mAb is specific
for an allelic determinant on the beta chain of a class II MHC
molecule. The HETCONJ complex thus can simultaneously
bind both to T cells and to genetically appropriate B cells to
form a molecular bridge between them.
The current investigation represents the initial characteriza-
tion of the specificity and efficacy of this HETCONJ reagent.
When added to spleen cells of B6 mice, a dose-dependent
proliferation was seen which presumably involved mainly T
cells. The proliferative effect of the HETCONJ reagent was
quantitatively similar to what was seen with the intact IgG anti-
CD3 monoclonal antibody. This proliferation apparently
required cell-cell interaction. This was demonstrated by the
complete failure of F(ab')2 fragments of the anti-CD3 mAb to
stimulate proliferation, and by the relative inability of the
HETCONJ reagent to stimulate bml2 spleen cells. Presumably,
the intact IgG anti-CD3 bound to macrophage and B-cell Fc
receptors via its Fc fragment, as well as to the TcR. Similarly, the
HETCONJ reagent bound to B cell and macrophage I-Ab
molecules, but not to I-A6 12. It is possible that the weak effect of
HETCONJ on bml2 spleen cells was due to a low affinity cross-
reaction of the D3-137.5 mAb with the bml2 Ia molecule.
We have also shown that the HETCONJ can mediate in vitro
T-cell dependent B-cell activation in a specific manner. Purified
B6.C20 B cells (I-Ab, Igha), in the presence of
(B6.C20 x bml2)Fl T cells, were activated in a dose-dependent
manner by the HETCONJ to generate large numbers of IgMa
PFC. As was the case in the proliferation assay, bml2 B cells
responded only weakly and inconsistently. This B-cell acti-
vation was not induced by a mixture of the F(ab')2 fragments of
the anti-CD3 and anti-I-A6 antibodies and did not occur in the
absence of T cells. Although these results demonstrate the
specificity of the HETCONJ reagent in B-cell activation, they do
not elucidate the mechanism of the effect.
A further set of experiments was, therefore, undertaken to
distinguish B-cell activation through the close apposition of
T cells and B cells (linked recognition) from that requiring only
soluble lymphokines liberated by activated T cells (bystander
effect). We mixed B6.C20 and bml2 B cells with F, T cells and
tested the activating effect of the HETCONJ. In a large number
of similar experiments, greater numbers of IgMa than IgMb PFC
were seen. This differential was not due to sensitivity of the
detection system, since LPS-stimulated B6.C20 and bm12
spleen cells, either mixed together or cultured separately, gave
comparable numbers of IgMa and JgMb PFC, respectively; and
(B6.C20 x bml2)F, B cells also gave equal numbers of a and b
allotype-antibody-forming cells when stimulated with the HET-
CONJ in the presence of F, T cells. These experiments indicate,
then, that the B-cell activation mediated by our HETCONJ
reagent preferentially involved direct T-B interaction (linked);
however, in all experiments a smaller but still significant amount
of activation of the non-recognized bm12 B cells was also seen
(bystander effect). The approximate relative magnitude of the
linked versus the bystander activation was 2: 1.
In additional studies, the differential requirements of B-cell
subsets for linked versus bystander activation was tested. Large
and small B cells were separated by density-gradient centrifuga-
tion. The former population presumably had been activated in
vivo, while the latter cells were considered to be resting. Results
indicated that the large B cells were more easily stimulated in
vitro to produce PFC, as would be expected from their activated
status. However, little evidence for T-B linkage preference in
their activation mechanism was seen. On the other hand, small
B cells gave a 10 times lower response than unseparated B cells.
This is in accordance with previous reports28'29 and reflects the
resting status of this population. However, there was a clear
preference for linked activation in small B cells, and the strength
of this preference was perhaps greater than that of the total
B-cell population.
The preference for linked B-cell activation mediated by our
HETCONJ reagent is not surprising. Normal T-B interaction
would involve recognition of an la/antigen complex by the TcR.
Our reagent, which links the TcR to Ta, mimics this interaction.
Of course, the details of the relative molecular configurations of
the TcR and la molecule must be somewhat different in the two
situations. In addition, our HETCONJ does not include a role
of nominal antigen. Antigen may provide an additional signal to
the B cell through its interaction with the surface IgM mol-
ecules.26 Furthermore, the Ia/antigen complex may interact with
the specific T cell in a manner beyond merely providing a ligand
for cross-linking.
According to the model by Noelle and Snow,30 B cells
become lymphokine responsive upon physical contact with
T-helper cells. This happens during specific T-B interaction, but
also when bystander resting B cells are in the presence of
activated T cells.3' Lymphokines such as IL-2 and IL-5,32 IL-433
or interferon-gamma34'35 released by T cells probably contribute
to B-cell activation. In the case of bml2 B cells, bystander
activation cannot involve TcR/Ia cross-linking. It is likely that
the anti-CD3 part of the HETCONJ, through the induction of
T-cell activation, increases the affinity of LFA-I for its ligand,
ICAM-1.9 In other systems, T-B interaction through these
accessory molecules has been shown to play an important role in
in vitro activation. Other T-cell surface molecules may also be
induced by the activation and explain the non-specific inter-
action with bml2 B cells and, thus, the bystander effect. In
addition, the anti-Ia part of the HETCONJ could inhibit the
normal CD4-class II interaction which takes place in a cognate
T-B interaction. These various factors may favour bystander
activation. However, the consistent preference for linked recog-
nition in our experiments suggests that the HETCONJ not only
brought T and B cells into contact, but mimicked some of the
events involved in T-B recognition, perhaps through a signal
mediated by the I-Al molecule. This interpretation is supported
by the finding that undigested anti-CD3 induced only one fourth
as many PFC as the HETCONJ, and gave an equal number of
IgMa and IgMb PFC (not shown). In any case, the additional
details of the mechanism of cognate interaction are not clear.
Specific T-B conjugates show capping of cytoskeletal compo-
nents ofT cells,37 and local focusing oflymphokine secretion can
be induced in response to an anti-TcR antibody.38 This polariza-
tion of the T cell in the process of cognate interaction is likely to
be part of an underlying molecular mechanism of T-B collabo-
ration, and may be more efficient when TcR Ads, rather than CD3
subunits, are cross-linked, since anti-TcR xfl and anti-CD3
mAb have been found to have different effects on T-cell
activation.39
The HETCONJ can also link T cells to other cells bearing
class II MHC molecules, for instance macrophages. It could be
5
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that these effects could lead to increased macrophage activation,
etc. However, this is unlikely to be the case with purified resting
B cells. While most of the phenomena are understandable as T-
B effects, T cells linked to other class II MHC-expressing cells
could also be perturbed and affect the results.
The current work extends previous use of heteroconjugate
antibodies to link specifically two cell types. In other systems,
tumours have been targeted for T-cell cytotoxicity, 42 or T-cell
help by T-cell clones has been directed at antigen-specific B
cells."3"5 In addition, in one system hybrid antibodies could
induce T-cell differentiation in thymic organ culture.43 The
present system permits the direct interaction of polyclonal T
cells with polyclonal B cells through a specific T-cell receptor-
MHC linking. This allows the use of normal cell populations to
explore in more detail further cellular and molecular aspects of
T-B collaboration. These possibilities include the role of
accessory molecules such as CD4; the cellular polarization
mentioned above; the role of immunoglobulin signalling for
B-cell activation, as opposed to antigen focusing; the role of
lymphokines and the effects of various subsets of B cells and
T cells on the efficacy and efficiency of such collaboration.
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